Experimental KRAS G12D Cancer Drug Shows Tumor Shrinkage in First-in-Human Trial
Setidegrasib, an investigational targeted therapy drug designed to eliminate the KRAS G12D protein, demonstrated encouraging early activity in a first-in-human clinical trial published in the New England Journal of Medicine. The international research team tested setidegrasib in patients with advanced lung and pancreatic cancers, observing tumor shrinkage and slowed cancer growth. KRAS G12D is a key cancer-driving protein that has historically been difficult to target with therapies. The trial results represent a potential breakthrough for patients with this mutation, offering a new treatment avenue for advanced cancers that previously had limited targeted therapy options.
First-in-Human Trial Results for Setidegrasib
▪The first-in-human clinical trial of setidegrasib was published in the New England Journal of Medicine.
▪A first-in-human clinical trial of setidegrasib was led by an international team of researchers.
▪Setidegrasib shows encouraging early activity in patients with advanced lung and pancreatic cancers in the first-in-human trial.
Targeting KRAS G12D Protein in Cancer Treatment
▪Setidegrasib is an investigational targeted therapy drug designed to eliminate the KRAS G12D protein.
▪KRAS G12D is a key cancer-driving protein.
Impact on Lung and Pancreatic Cancer Patients
▪Setidegrasib was tested in patients with advanced lung cancers in the first-in-human trial.
Perspective of International research team conducting the setidegrasib trial
▪The setidegrasib trial results represent encouraging early activity against KRAS G12D mutations in advanced cancers.
▪KRAS G12D has been historically difficult to treat with targeted therapies.
Perspective of Patients with KRAS G12D-mutated cancers
▪Setidegrasib represents a potential new treatment option for patients with KRAS G12D-mutated cancers.
▪The setidegrasib trial demonstrated the drug's ability to slow cancer growth in patients with advanced disease.
Story comments
Loading comments…